[Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].

Autor:	Zherebtsova VA; Botkin City Clinical Hospital., Vorobyev VI; Botkin City Clinical Hospital., Gemdzhian EG; National Research Center for Hematology., Ulyanova MA; Botkin City Clinical Hospital., Chernikov MV; Research Institute of Health Organization and Medical Management., Ivanova VL; Botkin City Clinical Hospital., Vinogradova OY; Botkin City Clinical Hospital., Ptushkin VV; Botkin City Clinical Hospital.
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2021 Jul 23; Vol. 93 (7), pp. 785-792. Date of Electronic Publication: 2021 Jul 23.
DOI:	10.26442/00403660.2021.07.200956
Abstrakt:	Background: Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial. Aim: Analysis of efficacy and safety of KRd in routine clinical practice. Materials and Methods: The prospective analysis included patients with MM who received at least one line of previous therapy. The inclusion criteria were relapse/progression; refractoriness; lack of very good partial response (VGPR) and more after the first line of therapy. Since February 2016, we used KRd like in ASPIRE trial, since October 2019, carfilzomib has been used at a dose of 56 mg/m2 on days 1, 8 and 15. Autologous hematopoietic stem cell transplantation (autoHSCT), consolidation (KRd) and maintenance therapy (Rd) were regarded as one line of therapy. Results and Discussion: We evaluated 77 patients with median age at the time of diagnosis is 55 (3072) years. For 56% (n=43) of patients KRd was applied as the second line (group 1), for 44% (n=34) as the third and more (group 2). In 23/43 patients from group 1, an early change in therapy was made due to insufficient effectiveness (after 24 courses of VCD or PAD). KRd served as a "bridge" to autoHSCT in 25 (32%) patients (21 of 25 in group 1). Another 7 patients underwent collection of autoHSC (all from group 1). The overall response rate (ORR) was 80.5%, with 33.8% complete response (CR) and 26% VGPR. ORR in group 1 was 98% versus 65.6% in group 2; 24-month overall survival (OS) was 70%, progression free survival (PFS) 49.8%. In group 1, 24-month OS was 85.6% versus 50.0% in group 2, 24-month PFS was 67.8% versus 25.5% (p=0.01). Conclusion: Our analysis confirmed the high efficiency of KRd in the treatment of RRMM in real-life practice. Early correction of therapy with insufficient effectiveness of the first line made it possible to implement the strategy of high-dose consolidation and autoHSCT in a larger percentage of patients with MM.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu